Patients from across the nation are reporting serious side effects caused by the blood-thinning drug Xarelto (Rivaroxaban). Complications such as stroke, brain hemorrhage, rectal bleeding, wound complications following total hip or knee arthroplasty and even death are being reported. There are nearly 20,000 lawsuits pending in state and federal courts: more than 18,560 have been consolidated under a federal multi-district in Louisiana; another 1,300 are pending in Philadelphia’s Complex Litigation Center. Three federal trials ended in victories for the drug-makers. The first trial in the Philadelphia proceedings was set to begin in late 2017.
There have been thousands of people that have come forward to make the claim that they were harmed due to the drug Xarelto (Rivaroxaban.) To date, there have been more than 18,000 suits filed that allege companies are getting rich while putting American citizens at risk of severe bleeds and even death.
First approved and hitting the market in 2011, Xarelto (Rivaroxaban) was released by Johnson & Johnson. J&J’s subsidiary Janssen Pharmaceuticals markets Xarelto in the U.S. Bayer is the manufacturer. Described as “the first and only one-a-day prescription anticoagulant blood thinner,” Xarelto was designed for patients suffering from a common heart condition called atrial fibrillation. Xarelto is prescribed to those who have an increased risk of blood clots primarily in patients who suffer from atrial fibrillation. The drug acts as a blood thinner to prevent or treat types of blood clots called deep vein thrombosis or pulmonary embolus. It is an anticoagulant that works by blocking certain proteins in the blood that contribute to clotting. Xarelto greatly reduces the risk of stroke in patients as well as removing the necessity for blood monitoring. Such tests are required for users of a much older blood thinner, warfarin (Coumadin). People using Xarelto (Rivaroxaban) have suffered from gastrointestinal, cranial, and retinal hemorrhaging. Worse, and unlike other anticoagulants, there is no way to turn off the anticoagulant effect of the drug, as there is with other anticoagulants, in an emergency. Doctors have seen patients bleed to death and had no way to stop it, due to this critical and potentially deadly shortcoming. Xarelto brought in over $2 billion for the Johnson & Johnson in 2016 alone and is on target to be one of the Top 20 grossing drugs on the market with sales approaching $3.7 billion in 2018.
With the drug Xarelto (Rivaroxaban), it is alleged in many of the pending suits is that the drug makers and marketers were well aware of the high risk involved, and did not adequately disclose that risk to doctors and patients. If proven, this claim would make the drug maker legally liable for damages to anyone who suffered the ill effects of the drug. While this claim is hotly denied by the drugs’ manufacturers, it is easy to see how this could happen. Billions of dollars in annual sales are at stake, and Xarelto remains a popular and heavily prescribed medication. Time after time, we as consumers have seen our safety traded for higher Big Pharma profits.
Currently, there are more than 2,000 class action cases involved in the Xarelto (Rivaroxaban) Settlements, but it is expected that several thousand additional cases will be filed in the future. The number of lawsuits is expected to grow however due to the fact that as more and more people take the drug, there is an increase in the number of people with adverse side effects. Plaintiffs in these cases are alleging that the company failed to provide patients with an adequate warning as to the severity of side effects that can accompany taking the drug. They are also claiming that the company fraudulently claimed the drug was safer than other drugs that are used for the same conditions through false advertising. It is alleged that the company also did not make consumers aware of the fact that there is not an antidote to treat the most severe and deadly side effect of Xarelto which is internal bleeding. In addition, it is alleged physicians were encouraged to prescribe the medication without proper knowledge of the severity of the risks of life-threatening side effects. Before taking Xarelto (Rivaroxaban) consult with a medical professional. The litigation mentioned on this page are not reflective of every case, so prior to taking any need medications, you should always seek the advice of your doctor or a specialist.
The Bellwether Trials and the MDL
In December of 2014, MDL 2592 was established by Lawyers in the Eastern District of Louisiana by the U.S. Judicial Panel on Multidistrict Litigation. On January 29, 2015, the first Xarelto MDL pretrial conference was held by Judge Fallon. After much preparation, the first case is set for trial in April 2017. The Eastern District of Louisiana will host the first two Bellwether trials which are set for April 24, 2017, which is the Joseph Boudreaux case, and the Joseph Orr case which is set for May 30, 2017. The next two Bellwether trials will be conducted in the Southern District of Mississippi in June 2017 and in the North District of Texas in July 2017.
The Boudreaux case was filed in December 2014. The plaintiff, in this case, claims that he was prescribed for his atrial fibrillation in order to reduce the risk of stroke. However, within a month of taking it, Mr. Boudreaux suffered from a severe and life-threatening gastrointestinal bleed. The plaintiff was hospitalized and received several blood transfusions.
In the Orr case, the plaintiff and her Lawyers allege that his wife, Sharon began taking Rivaroxaban in May 2015 for atrial fibrillation. It is alleged that within one month of her using Rivaroxaban she developed a brain hemorrhage and died after being hospitalized and suffering for 10 days from the bleed.
Plaintiffs in these cases are alleging that the company failed to provide patients with an adequate warning as to the severity of side effects that can accompany taking the drug. They are also claiming that the company fraudulently claimed the drug was safer than other drugs that are used for the same conditions through false advertising. It is alleged that the company also did not make consumers aware of the fact that there is not an antidote to treat the most severe and deadly side effect of Xarelto which is internal bleeding. In addition, it is alleged physicians were encouraged to prescribe the medication without proper knowledge of the severity of the risks of life-threatening side effects.
If you or someone you know has suffered life-threatening side effects or death you may be entitled to receive compensation for your suffering. If you have suffered from any side effects or health complications from the use of Xarelto (Rivaroxaban), we can help you. To get your claim stated, please feel free to fill out our Defective Drug Evaluation by clicking HERE and our Jones Brown Team will get to work.
Contact Jones Brown Law
There are countless medications and devices on the market or that have recently been taken off of the market that has affected the lives of unknowing victims worldwide. The hardest part is getting this information out to these victims. Here you will find a list and all the information you need if you feel that you or a loved one has fallen victim to a defective drug or defective medical devices.
Jones Brown Law has worked hard to research some of these current medications and devices out here to give you the most accurate and up-to-date information available. Our Jones Brown Law team has experience helping countless victims of defective drugs and devices. We understand each case is different, however, we will help you recover what you are entitled to and we understand what you are going through when you are dealing with a defective drug lawsuit or a defective medical device lawsuit.
When you need legal help, finding the answers you need can be overwhelming. No fear, you can contact us! We’re here to take the guesswork and searching out of the equation. Contact us: call, text, or fill out the form below, and we will contact you within 24 business hours.
You May Call Us
855-JBLAW99 (855-525-2999) We answer our phones 24 hours a day.
Text Us For A Quick Response
- Frank Peck v. Janssen Research & Development LLC, et al. Complaint and Jury Demand. (2015,April 29).
- Harry Griggs and Joseph Griggs v. Janssen Research & Development LLC. Complaint and Demand for Jury Trial. (2014, August 14).
- In Re: Xarelto (rivaroxaban) Products Liability Litigation. Transfer Order. (2014 December 12). Retrieved from:https://www.unitedstatescourts.org/federal/nyed/360190/28-0.html
- Johnson & Johnson. (2016). Quarterly Sales and Earnings. Retrieved from:http://files.shareholder.com/downloads/JNJ/1922283046x0x886528/EE097E51-DF15-430F-923C-3C00865CD3D7/1Q2016_Final_combined_file.pdf
- Krajelis, B. (2013, January 10). Herndon reports steady progress in Yaz, Pradaxa litigation. The Madison-St. Clair Record. Retrieved from:http://madisonrecord.com/issues/895-product-liability/251351-herndon-reports-steady-progress-in-yaz-pradaxa-litigation
- Nancy Packard v. Janssen Research & Development LLC, et al. Jury Demanded. (2014 June 23). Retrieved from:https://www.unitedstatescourts.org/federal/flsd/444053/1-0.html
- Pierson, R. (2012, June 14). Pradaxa and Xarelto: Top heart doctors concerned over new blood thinners. Retrieved from:https://www.huffingtonpost.com/2012/06/14/pradaxa-xarelto-blood-thinner-doctors-heart_n_1595971.html
- Raymond. N. (2017). Bayer, J&J win first trial over Xarelto bleeding risks. Retrieved from:http://www.reuters.com/article/us-bayer-xarelto-idUSKBN17Z2HW
- Ruth E. McGowan v. Janssen Research & Development LLC, et al. Complaint and Demand for Jury Trial. (2014 July 25).
- Salvatore, C. (2017). Bayer, Janssen Win 2nd Xarelto Bellwether Trial. Retrieved from:https://www.law360.com/articles/933887/bayer-janssen-win-2nd-xarelto-bellwether-trial
- United States Judicial Panel on Multidistrict Litigation. (2017). MDL Statistics Report – Distribution of Pending MDL Dockets by District. Retrieved from:http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-September-15-2017.pdf